pembrolizumab: defining standards of care in urothelial cancer
Published 6 years ago • 65 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
0:58
replacing the current standard of care for urothelial carcinoma
-
2:18
ema restrict pembrolizumab/atezolizumab usage in urothelial cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
1:36
pembrolizumab in urothelial cancer
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
56:27
ccf webinar: a clinical trial for a potential new ther2apy for biliary tract cancers
-
2:21
dr. galsky on maintenance pembrolizumab in urothelial cancer
-
2:31
key immunotherapy combinations for urothelial cancer
-
0:50
maintenance therapy for patients with advanced urothelial carcinoma
-
2:41
firstline pembrolizumab for metastatic urothelial cancer
-
1:58
results for first-line pembrolizumab in advanced urothelial carcinoma
-
4:46
changing the standard of care in metastatic bladder cancer
-
4:34
optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma
-
2:21
precision medicine in urothelial carcinoma
-
3:16
keynote-057 update: pembrolizumab for high-risk nmibc patients
-
2:15
results of a first-line study of pembrolizumab in advanced urothelial cancer